SCHEMBL12019300

SCHEMBL12019300

N=C(N)NCCC[C@@H]1NC(=O)[C@H](CCCCNC(=O)CN2CCCN3CCCN(CCCN(CC(=O)O)CC3)CC2)NC(=O)[C@@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ITGB3 P05106 10/20 0.46
▸ ITGA2B P08514 5/20 0.46
▸ ITGAV P06756 5/20 0.45
▸ ITGB1 P05556 2/20 0.45
▸ ITGA5 P08648 2/20 0.45
▸ ITGB5 P18084 3/20 0.45
▸ MC4R P32245 4/20 0.44
▸ MC5R P33032 4/20 0.44
▸ MC3R P41968 4/20 0.44
▸ MC1R Q01726 4/20 0.44
▸ CACNA1B Q00975 1/20 0.44
▸ ELANE P08246 2/20 0.43
▸ KEAP1 Q14145 1/20 0.43
▸ NFE2L2 Q16236 1/20 0.43
▸ CTSG P08311 1/20 0.43
▸ KDM4A O75164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19362494 0.95 ITGB3 (0.50) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL17178028 0.92 ITGB3 (0.46) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL12019244 0.87 CACNA1B (0.42) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL29393726 0.85 ITGB3 (0.59) ITGB3ITGA2BITGAVITGB5MC4R
SCHEMBL16301538 0.84 ITGB3 (0.55) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL23802740 0.83 ITGB3 (0.47) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL18132947 0.83 ITGB3 (0.53) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL23823920 0.83 CACNA1B (0.53) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL24285405 0.83 ITGB3 (0.53) ITGB3ITGA2BITGAVITGB1ITGA5
SCHEMBL16135240 0.83 ITGB3 (0.54) ITGB3ITGA2BITGAVITGB1ITGA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353120-B2 Tetraaza macrocyclic compound, preparation method thereof and use thereof KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2016-05-31 — — US disclosed
US-9061078-B2 Tetraaza macrocyclic compound, preparation method thereof and use thereof KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2015-06-23 — — US disclosed
US-20120219495-A1 NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2012-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219495-A1 NOVEL TETRAAZA MACROCYCLIC COMPOUND, PREPARATION METHOD THEREOF AND USE THEREOF TBCA, NBAS, BMP2 ITGB3 3342/4885ITGA2B 1874/4885ITGAV 3020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback